Literature DB >> 24975913

Clinical trials in patients with heart failure and preserved left ventricular ejection fraction.

John G F Cleland1, Pierpaolo Pellicori2, Riet Dierckx2.   

Abstract

There is no robust evidence that any treatment can modify the natural history of patients with heart failure and preserved left ventricular ejection fraction (HFpEF), although most agree that diuretics can control congestion and improve symptoms. HFpEF is often complicated by systemic and pulmonary hypertension, atrial fibrillation, obesity, chronic lung and kidney disease, lack of physical fitness, and old age that can complicate both diagnosis and management. Further trials should phenotype patients precisely and create better definitions of HFpEF based on biomarkers.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trials; Comorbidity; HFpEF; NT-proBNP

Mesh:

Substances:

Year:  2014        PMID: 24975913     DOI: 10.1016/j.hfc.2014.04.011

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  8 in total

1.  Molecular Signature of HFpEF: Systems Biology in a Cardiac-Centric Large Animal Model.

Authors:  Andrew A Gibb; Emma K Murray; Deborah M Eaton; Anh T Huynh; Dhanendra Tomar; Joanne F Garbincius; Devin W Kolmetzky; Remus M Berretta; Markus Wallner; Steven R Houser; John W Elrod
Journal:  JACC Basic Transl Sci       Date:  2021-08-23

Review 2.  Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?".

Authors:  Peter Moritz Becher; Nina Fluschnik; Stefan Blankenberg; Dirk Westermann
Journal:  World J Cardiol       Date:  2015-09-26

3.  HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction.

Authors:  Markus Wallner; Deborah M Eaton; Remus M Berretta; Laura Liesinger; Matthias Schittmayer; Juergen Gindlhuber; Jichuan Wu; Mark Y Jeong; Ying H Lin; Giulia Borghetti; Sandy T Baker; Huaqing Zhao; Jessica Pfleger; Sandra Blass; Peter P Rainer; Dirk von Lewinski; Heiko Bugger; Sadia Mohsin; Wolfgang F Graier; Andreas Zirlik; Timothy A McKinsey; Ruth Birner-Gruenberger; Marla R Wolfson; Steven R Houser
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 19.319

4.  Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction.

Authors:  Elia C El Hajj; Milad C El Hajj; Brandon Sykes; Melissa Lamicq; Michael R Zile; Robert Malcolm; Patrick M O'Neil; Sheldon E Litwin
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

5.  Frequent cyclic variation of heart rate is associated with left ventricular diastolic dysfunction in patients without ischemia.

Authors:  Takanori Yaegashi; Manabu Nakano; Yoshiharu Murata
Journal:  Health Sci Rep       Date:  2021-12-21

6.  Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.

Authors:  In-Jeong Cho; Seok-Min Kang
Journal:  Kidney Res Clin Pract       Date:  2021-11-22

Review 7.  Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel
Journal:  J Am Heart Assoc       Date:  2016-01-25       Impact factor: 5.501

8.  In silico identification of potential calcium dynamics and sarcomere targets for recovering left ventricular function in rat heart failure with preserved ejection fraction.

Authors:  Stefano Longobardi; Anna Sher; Steven A Niederer
Journal:  PLoS Comput Biol       Date:  2021-12-06       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.